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Abstract 
Primary screening for cervical cancer is transitioning from the longstanding Pap smear towards 
implementation of an HPV-DNA test, which is more sensitive than Pap cytology in detecting 
high-risk lesions and offers greater protection against invasive cervical carcinomas. Based on 
these results, many countries are recommending and implementing HPV testing-based screening 
programs. Understanding what factors (e.g., knowledge, attitudes) will impact on HPV test 
acceptability by women is crucial for ensuring adequate public health practices to optimize 
cervical screening uptake. We used mixed methods research synthesis to provide a categorization 
of the relevant factors related to HPV primary screening for cervical cancer and describe their 
influence on women’s acceptability of HPV testing. We searched Medline, Embase, PsycINFO, 
CINAHL, Global Health and Web of Science for journal articles between January 1, 1980 and 
October 31, 2017 and retained 22 empirical articles. Our results show that while most factors 
associated with HPV test acceptability are included in the Health Belief Model and/or Theory of 
Planned Behavior (e.g., attitudes, knowledge), other important factors are not encompassed by 
these theoretical frameworks (e.g., health behaviors, negative emotional reactions related HPV 
testing). The direction of influence of psychosocial factors on HPV test acceptability was 
synthesized based on 14 quantitative studies as: facilitators (e.g., high perceived HPV test 
benefits), barriers (e.g., negative attitudes towards increased screening intervals), contradictory 
evidence (e.g., sexual history) and no impact (e.g., high perceived severity of HPV infection). 
Further population-based studies are needed to confirm the impact of these factors on HPV-
based screening acceptability. 
Keywords: Human papillomavirus; Uterine Cervical Neoplasms; Mass Screening; Psychology; 
Human Papillomavirus DNA Tests; Review; Mixed methods; Barriers; Facilitators; Psychosocial 
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Introduction 
 Globally, 530,000 cervical cancers cases per year are attributable to the human 
papillomavirus (HPV) and represent 8% of all cancers occurring worldwide[1]. The 
understanding of the causal connection between persistent infection with high-risk HPV types 
and cervical cancer[2, 3] has led to new primary and secondary prophylaxis measures. Although 
primary prophylaxis of cervical cancer through HPV vaccination is considered a major 
achievement, secondary prophylaxis through screening will remain extremely important in 
addressing cervical cancer for decades to come because current HPV vaccines do not offer 
protection against all high-risk HPV types, HPV vaccine uptake is variable across the globe and 
the ultimate length of protection provided by vaccination is to be established yet[4].  
Historically, the mainstay of cervical cancer screening was represented by cytology (i.e., 
Papanicolaou or Pap test) to screen for cervical cellular abnormalities. In recent years, HPV 
DNA tests (hereafter HPV test or testing) capable of identifying high-risk HPV types have been 
developed. Multiple studies have shown that HPV testing is more sensitive than cytology in 
detecting cervical intraepithelial neoplasia in primary cervical cancer screening (hereafter 
primary screening)[5-8] and has similar specificity compared to Pap testing in women aged 30 
and older[9]. Overwhelming evidence suggests that a negative HPV test provides more 
reassurance to a woman that she is at low-risk for cervical lesions than a negative Pap test and 
supports the extension of intervals in primary screening beyond 5 years [3, 10, 11].  
This evidence has led to new recommendations that incorporate HPV testing as a primary 
screen for cervical cancer in women aged between 30 and 65 years, either as a stand-alone 
test[12-14] or with cytology (i.e., co-testing)[15-17].  
Misunderstandings and misconceptions related to HPV testing,  fueled by lack of HPV or 
HPV testing knowledge (e.g., purpose of HPV testing, causal relationship between HPV and 
cervical cancer, natural history of HPV infection) in Australian women[18], lead to a petition 
signed by more than 70 000 women against the roll out of the new primary cervical cancer 
screening program (HPV test every 5 years in women aged 25 to 74 years instead of Pap test 
every 2 years); consequently, the implementation of the program was postponed from May 1 to 
December 1, 2017[14, 19].  
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No synthesis has been carried out to examine what factors’ impact (e.g. facilitators, 
barriers) on HPV test acceptability in primary screening. As new guidelines have been developed 
and are in the process of being implemented worldwide, we aimed to provide a comprehensive 
description of psychosocial factors related to HPV testing and to assess their influence on HPV 
testing acceptability in primary screening for cervical cancer with the ultimate goal to guide 
interventions to promote screening.  
Methods 
We used mixed methods research synthesis (MMRS), which is a form of systematic 
review[20-22], to answer following research questions: “What are the psychosocial factors 
related to HPV testing in primary screening for cervical cancer?” and “What is the influence of 
these factors on women’s acceptability of HPV testing in primary screening for cervical 
cancer?”. By selecting MMRS, we highlight our opinion that preventive behaviors (e.g., 
participating in screening) are complex and can be best understood by combining views of 
constructivism (subjectivity, associated with qualitative research) with views of logical 
empiricism (objectivity, associated with quantitative research). In integrative MMRS, findings of 
empirical qualitative, quantitative or mixed methods experimental or observational studies are 
treated as primary data that are analyzed and synthesized by using mixed methods 
approaches[20-22] (Figure 1). The PRISMA framework was used to guide the reporting of this 
review[23]. The protocol was registered on International Prospective Register of Systematic 
Reviews (PROSPERO), registration #CRD42017078254
1
.  
We searched Medline, Embase, PsycINFO, CINAHL, Global Health and Web of Science 
for journal articles between January 1, 1980 and October 31, 2017. The search strategy was 
developed for Medline by our team, validated by an experienced McGill librarian and then 
adapted for the other databases (Appendix A). The following eligibility criteria were applied: 1) 
Population: women of all ages for whom primary cervical cancer screening is recommended, 2) 
Outcome: psychosocial factors related to acceptability of HPV testing in primary screening for 
cervical cancer
2
, 3) Study design: empirical studies, without restrictions of study methodology, 
                                                          
1
 available at https://www.crd.york.ac.uk/prospero/ 
2
 In primary screening for cervical cancer, HPV testing is used in women with no history of cervical 
cytological abnormalities i.e., abnormal Pap results. Because women will be in various stages of 
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4) Languages: English or French or German. The selection of references was performed by two 
researchers (OT and AN).  
Records were first screened for eligibility based on titles and abstracts (phase one). Then, 
the full texts of retained records were retrieved and read; the final set of articles was identified 
based on eligibility criteria (phase 2). Disagreements in phase one and two on whether or not an 
article should be included were mediated by the senior researcher (ZR). For this review, we did 
not retain studies related to self-sampling which represents a distinct strategy to increase 
screening uptake and merits separate consideration. A data extraction sheet was developed in 
Excel and included author, title, publication date, country, objectives, study design, quantitative 
data collection and analysis methods, qualitative methodology, qualitative data collection 
methods and analysis, and number of participants. From qualitative studies, we extracted 
qualitative raw data without any interpretation or analysis (e.g., quotes). From quantitative 
studies, we extracted outcomes of acceptability (e.g. proportions, means, odds ratios).  
The risk of bias in individual studies was assessed separately by two researchers (OT and 
ET), with the 16-item Quality Assessment Tool for Studies with Diverse Designs (QATSDD), a 
valid and reliable instrument developed for appraising studies in the disciplines of psychology, 
sociology and nursing[24]. For overall scores ≤60% and > 60% we report high and low risk of 
bias respectively. All articles were included in the analyses, independent of their quality as we 
aimed to provide a comprehensive synthesis of factors.  
We used a sequential exploratory (QUAL → quan) mixed methods design to analyze and 
synthesize findings of retained studies[22, 25, 26]. In the first phase, qualitative (QUAL), 
qualitative data from all qualitative and quantitative studies was analyzed; psychosocial factors 
measured in quantitative studies (e.g., anxiety, embarrassment, number of lifetime sexual 
partners, history of cervical screening) were treated as qualitative data[26]. We performed 
deductive-inductive qualitative thematic analysis to identify factors related to HPV testing. 
Deductively, we identified themes based on two frameworks widely used in health behavior 
research: The Health Belief Model (HBM)[27] and the Theory of Planned Behavior (TPB)[28]. 
Inductively, we developed new themes (i.e., not covered by HBM and TPB) through an iterative 
process, which consisted of reading the studies (and new themes) multiple times, allowing 
                                                                                                                                                                                           
understanding the issue in terms of knowledge, attitudes and actual behavior, for the purposes of this 
paper we collapsed outcomes of intentions, willingness and uptake into the overarching term 
‘acceptability’. 
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researchers to assure accurate interpretation of study results. Themes (hereinafter called factors) 
were further grouped into categories to enable a structured reporting of the results of the 
qualitative phase. The factors and categories were developed independently by two researchers 
(OT and ET) and then validated by the research team. The second (quan) phase was informed by 
the first, (QUAL) phase; for each factor, based on quantitative findings (only where statistical 
tests for significance were reported), we provide a narrative synthesis of their influence on HPV 
testing acceptability. As part of the mixed research synthesis, we developed an integration matrix 
to match each identified factor with the quantitative evidence (for each quantitative study) of its 
impact on HPV testing acceptability. This approach allowed us to further synthesize the direction 
of influence of each factor on HPV testing acceptability into four categories: 1) possible barrier 
(PB, factor identified as a barrier in at least one study), 2) possible facilitator (PF, facilitator in at 
least one study), 3) contradictory evidence (CE), when two directions of influence (barrier and 
facilitator) were found for the same factor across studies and 4) no impact (NI), meaning that 
only evidence for no association was found. The narrative synthesis is organized based on the 
synthesized direction of influence of each factor on HPV testing acceptability. 
Results 
I. Summary of included studies and study quality 
The study selection flow diagram is presented in Figure 2. We retained 22 primary 
studies: 5 of qualitative methodology[29-33], 15 of quantitative methodology[34-48] and 2 in 
which both methodologies were used[49, 50]. Seventeen studies originate in high income 
countries (8-USA, 2-Canada, 5-Europe and 2 in Australia) and five in low and middle income 
countries (1-Mexico, 1-El Salvador, 1-China, 1-India and 1 in Nigeria). In 14 quantitative 
studies, statistical tests of significance to assess acceptability were reported; these studies were 
included in the integration phase. 
Quality appraisal revealed low risk of bias in 18 studies and high risk of bias in 4 
studies[40, 42, 45, 49]. Among low risk of bias studies, only six were guided by an explicit 
theoretical framework[29-31, 40, 44, 50] or provided evidence of pilot testing of the data 
collection tool[29, 32, 37-39, 41]. In high risk of bias studies, theoretical frameworks were not 
used, the validity and reliability of the measurement tools was not assessed, no sample size 
calculations were provided[40, 42, 49] and few details were provided related to the recruitment 
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procedure and research setting[45]. Characteristics of included studies and results of quality 
appraisal are provided in Table 1. 
II. Qualitative synthesis  
1. Knowledge 
Studies examined three types of knowledge: cervical cancer screening, HPV, and HPV 
testing. Cervical cancer screening knowledge includes women’s awareness of current cervical 
cancer screening guidelines[40] and implications of HPV vaccination campaigns on the need for 
screening[31]. Low levels of knowledge may have a particularly negative impact on HPV test 
acceptability: “But if I don’t know anything about cervical cancer, I will hesitate”[29]. HPV 
knowledge covers information gaps, such as mode of transmission[31-33] "I have a sister who 
came down with human papillomavirus and it got me thinking and that's why I decided to get 
tested"[30], causal relationship with cervical cancer[31, 37, 47] “I don't think I've ever thought of 
it (i.e., association between HPV and cervical cancer) in that sense"[33]. HPV test knowledge 
emerged as a factor since lack of knowledge contributes to women’s fear of testing[29]. 
Additionally women were unsure about differences between the HPV test and the Pap test[30, 
31, 33, 47], were not familiar with the test procedure[30, 31] or had difficulties interpreting the 
results[32, 37]. 
2. Attitudes, beliefs and subjective norms 
Women’s attitudes and beliefs are centered around four domains: cervical cancer, 
cervical cancer screening, HPV infection and HPV testing. Perceived severity of cervical cancer 
e.g., “desire to protect one’s family and one’s ability to care for their family”[32] was viewed as 
a reason to participate while “fear of receiving a cancer diagnosis and treatment”[32] was a 
reason to refuse HPV testing. Low perceived susceptibility of cervical cancer e.g., “I have never 
thought that you catch cervical cancer through having too much sex”[33] or perceiving low risk 
of cancer e.g., “not knowing anyone who had cervical cancer” were reasons for refusing HPV 
testing[32, 38].  
Attitudes towards cervical cancer screening include delayed start of screening e.g., "Age 
25 is too late. I had a 19-year-old staff member with cervical cancer”[50] and/or increased 
screening interval e.g., “I worry that only being tested every 4 years gives plenty of time for 
issues to arise and go untreated"[50], Pap versus HPV test preference[32, 48, 50] and general 
attitudes and beliefs e.g., presence of early signs and symptoms in cervical cancer[29] or 
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physical discomfort "I don't like to get a Pap smear or anything like that, because every time I 
have one, they have hurt me”. [32]. When both HPV testing and Pap are available, womens’ 
decision depends on the screening test preference[48, 50].  
The factor perceived severity of HPV infection includes the assumption that HPV testing 
is performed because HPV “must be a serious disease”[30] and the factor perceived 
susceptibility of HPV infection includes perceived risk of getting a HPV infection[48], including 
the relative protection offered by a monogamous relationship[32].  
Perceived benefits of the HPV test synthesize women’s beliefs of the HPV test being 
accurate for early detection of cancer[29, 38, 46, 50] despite possible concerns about the HPV 
test safety[29, 50]  and negative emotions and perceptions related to HPV testing such as anxiety 
about the test results[29], stigma and problems with communicating of positive results to 
significant others[33].  
Subjective norms comprise healthcare provider (HCP) recommendation[29, 36, 38, 39, 
44, 46, 49, 50], screening guidelines[29, 40, 44, 50], and the opinions of spouse and friends[29, 
40, 42, 44, 50]. 
3. Health behaviors, adherence, emotional and behavioral control 
HPV vaccination status[40], history of health check-up[48], including screening for 
breast cancer[48], usage of birth control methods (e.g., contraceptives)[36, 43] and smoking 
history were synthesized as health behaviors. Adherence to cervical cancer screening depends 
on the age of the first Pap[40], history of time-appropriate Pap testing[36, 37, 40, 42, 48] and 
intentions to screen with the Pap test[48]. Perceived emotional reaction to HPV results plays an 
important role, because women could feel embarrassed[32] or concerned[48] by a positive HPV 
test result and therefore be reluctant to share the test outcome with their partner or close 
friends[48] who could show variable level of understanding[44, 50]. Perceived behavioral 
control e.g., “I am confident that I could have an HPV test to screen for cervical cancer instead 
of a Pap smear”[50] represents an emerging factor in the context of increased options for primary 
cervical cancer screening. 
4. Health information channels, healthcare system factors and interventions 
Women use multiple health information channels to increase their knowledge[42], which 
emphasizes the importance of HCP in disseminating critical information about HPV testing[33]. 
Healthcare system factors such as health insurance status[35], availability of screening 
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facilities[29], and type of primary care provider (e.g., family practitioner, gynecologist)[48] can 
determine screening acceptability. Interventions to increase cervical screening participation 
include: personalized screening invitation letters[34, 37], information leaflets[34], screening 
reminder phone calls[34], and HPV and cervical cancer prevention education[41, 45]. 
5. Personal factors 
General health status[37, 39], history of abnormal Pap test[38, 40, 48], past medical 
history e.g., cancer[36, 39], cardiovascular disease, diabetes, depression[36], history of STI’s[35, 
36] are grouped under personal medical history and health status. Having a family member with 
cervical or other malignancies[32, 36, 39, 40] is grouped under family medical history. Age at 
first sexual intercourse[36, 40], number of lifetime sexual partners[36, 44, 48, 50] and sexual 
orientation[35] are summarized as sexual history. Finally, sociodemographics encompass widely 
used categories, e.g., age[31, 35, 37-40, 42-44, 48, 50], relationship status[35-37, 39, 40, 42-44, 
48, 50]), and education[35-40, 42-44, 48, 50]. 
III. Integration of qualitative and quantitative results and quantitative synthesis 
We used an integration matrix to match each factor (rows) with their influence on HPV 
test acceptability (e.g., facilitator) based on quantitative results of primary studies (columns) (see 
Appendix B). The overall effect of each factor on HPV test acceptability (e.g., possible 
facilitator) is provided in the last column, e.g., for high perceived benefits of the HPV test, 
evidence of no impact (NI)[40] and facilitator (F) [44, 50] were found, thus this factor was 
synthesized as possible facilitator (PF). Final MMRS results are displayed in Figure 3 where 
factors are organized based on their overall effect on HPV test acceptability and their theoretical 
framework roots (i.e., HBM or TPB or new factor). The narrative synthesis of quantitative results 
of primary studies is organized by results of the integration matrix and results of qualitative 
synthesis i.e., for each direction of influence (e.g., possible facilitators), factors corresponding to 
each category (e.g., knowledge, then attitudes, beliefs and subjective norms, etc.) are described 
sequentially. 
1. Possible facilitators 
Increased HPV and HPV test knowledge were associated with higher HPV test 
acceptability (OR=1.47; 95% CI=1.13-1.90 and OR=1.70; 95% CI=1.17-2.45 respectively)[37].  
Burger et al. found a significant association between higher perceived severity of cervical 
cancer and HPV test acceptability (OR =1.92; 95% CI=1.32-2.80)[37]. Higher perceived 
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susceptibility of cervical cancer was either associated with higher HPV test acceptability 
(OR=1.47; 95% CI=1.05-2.06)[37] or had no effect[48]. Higher perceived susceptibility of HPV 
infection was associated with higher HPV test acceptability; the association was not significant 
for perceived susceptibility of genital warts[48].General attitudes and beliefs related to cervical 
cancer screening (i.e., considering the Pap test to be very important in preventing cervical 
cancer) was associated with increased HPV test acceptability (OR=3.50; 95% CI= 1.64-
7.50)[37]. Based on a relative small sample of 149 Australian women, Jayasinghe et al. found no 
significant association between perceived benefits of the HPV test and HPV test acceptability 
(Fisher exact test, p=0.2)[40] while Ogilvie et al., on a sample of 981 Canadian women 
concluded that perceiving higher benefits was associated with higher acceptability of HPV 
testing regardless of age the screening starts (OR=1.22; 95% CI=1.15-1.30)[44] or at ≥ 25 years 
at a 4 years interval (OR=1.26; 95% CI=1.23-1.30)[50]. Higher perceived HPV test safety was 
associated with higher HPV test acceptability[44]. Higher subjective norms (i.e., higher 
perceived influence from significant others, HCP, screening guidelines) was associated with 
higher HPV test acceptability[40, 42, 44, 50].  
Related to health behaviors, positive HPV vaccination status was associated with higher 
acceptability to receive the HPV test starting at age 25 at a 5-year interval compared to Pap 
testing every 2 years[40]. Contraception use was associated with higher HPV test acceptability 
(OR=1.63; CI=1.5-1.7)[43]  and no association with the method of contraception was found [36]. 
Smoking history did not significantly influence HPV test acceptability[44, 48, 50]. Adherence to 
cervical screening recommendations (e.g., screening at intervals ≤ 3 years) was either associated 
with higher acceptability of HPV testing[36, 37, 42] or no association was found[39, 40, 48]. 
Increased behavioral control of getting the HPV test instead of the Pap test was found in two 
studies to increase HPV test acceptability[44, 50], while in another study to have no effect on 
HPV test acceptability[40].  
Women who communicated with friends about health issues, or, who gathered 
information from media or leaflets reported higher HPV test acceptability[42]. Surprisingly, 
discussing health issues with HCP and gathering information via internet were not significantly 
associated with HPV test acceptability[42]. Among healthcare system factors, being screened in 
a clinic that offered HPV testing in primary cervical cancer screening was associated with 
increased HPV test acceptability compared to Pap[48]. Other factors, such as health insurance 
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status[35, 39], and distance from the clinic and transportation facilities were not related to HPV 
test acceptability[36].  
In terms of sociodemographics, non-whites were found to have lower acceptability than 
whites[42], except for Latina[39]. Education was found to either have no impact [35-40, 44, 48] 
or increase[42, 43, 50] HPV test acceptability. Higher income is a possible facilitator as we 
found that income can increase[37, 48] or have no effect[35, 39, 40, 42] on HPV test 
acceptability.  
2. Possible barriers 
Women expressing concerns about delayed start of screening had significantly lower 
acceptability of the HPV test if the screening start is delayed to 25 years and continues at a 5-
year interval[40]. Increasing the screening interval from 1 to 3 years had no significant influence 
on HPV test acceptability[40, 48]. For five years between screening, acceptability was either 
similar to yearly intervals[48] or decreased (OR=0.2; CI=0.1-0.4)[40], while for 10-year 
screening interval acceptability was lower (OR=0.05; CI=0.03-0.1)[40]. Negative emotions and 
perception related to HPV testing significantly increased acceptability of Pap compared to HPV 
testing (PR=1.39; 95% CI=1.07-1.80)[48]. In most studies, marital status was not associated[35, 
36, 39, 42, 44, 48, 50] with HPV test acceptability but evidence exists that being single (versus 
married)[37, 43] is related to lower acceptability.  
3. Contradictory evidence 
Negative perceived emotional reaction to HPV results can either augment (i.e., higher 
concern about a positive HPV test)[48], diminish (i.e., women reluctant to share a positive HPV 
result with their partner)[37] or have no effect HPV test acceptability[44, 50]. In terms of 
screening test preference, when both Pap and HPV tests are offered, preference for a test is 
associated with higher acceptability i.e., increased HPV test acceptability (OR = 1.26; CI = 1.23-
1.30)[50] or increased Pap acceptability (60.7% for Pap, CI = 56.5-65.7)[48]. 
Related to existing personal medical history, poor or very poor self-reported health status 
was found to decrease (OR= 0.49; CI = 0.27-0.91)[37] or have no significant effect[39] on HPV 
test acceptability. Reporting personal history of cancer (other than cervical) increased[39] or had 
no effect on HPV test acceptability[36]. Reporting previous cervical cytological abnormalities 
either decreased (OR = 0.65; CI = 0.46-0.94)[38] or had no impact[48] on HPV test 
acceptability. With respect to obstetric history, compared to nulligravidae, women who reported 
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pregnancies had higher HPV test acceptability (OR = 2.10; CI= 1.80-2.40)[43]. Other personal 
medical history correlates e.g., history of STI, menopausal status, Body Mass Index, 
cardiovascular diseases, diabetes and depression were not associated with HPV test 
acceptability[35, 48]. Among sexual history, reporting 4 or more[36] or zero[35] lifetime sexual 
partners was associated with lower HPV test acceptability and reporting both male and female 
lifetime partners increased HPV test acceptability (OR=1.75; CI=1.39-2.20)[35]. Evidence 
related to age is contradictory; older women (e.g., ≥ 40) were found to have either increased[38, 
39] or decreased[37, 42, 43] HPV test acceptability.  
In 60-70 year old women, interventions in form of personalized letters signed by their 
physician and an informative leaflet explaining the most important reasons for screening for 
cervical cancer significantly increased HPV test acceptability (screening coverage increased with 
31.6%, CI=29.0-34.1, p≤0.05)[34]. In a nationally representative sample of Norwegian women, 
Burger et al. found that using invitation letters for HPV testing (i.e., stating that HPV testing at a 
6-year interval will replace Pap testing) resulted in marginally lower HPV test acceptability 
(strength of intention, p=0.008) compared to using Pap testing invitation letters (i.e., at a 3-years 
interval)[37]. Educational interventions were found to have either equivocal[45] or positive 
effect[41] on HPV test acceptability. 
4. No impact  
Cervical cancer screening knowledge was not associated with HPV test acceptability[40, 
48]. Higher perceived severity of HPV infection had no significant effect on women’s 
acceptability of the HPV test[37]. 
Family medical history of cancer was not associated with HPV test acceptability[36, 39]. 
Discussion 
In our mixed methods research synthesis, we analyzed findings of empirical qualitative 
and quantitative studies and: a) provided an up-to-date and comprehensive list of factors specific 
for HPV test acceptability in primary screening for cervical cancer, b) synthesized factors’ 
direction of influence on HPV test acceptability and c) described factors’ impact on HPV test 
acceptability.  
Our results show that factors associated with HPV test acceptability are complex; while 
many factors are included in the HBM and/or TPB (e.g., attitudes, perceived behavioral control), 
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other relevant factors are not encompassed by these theoretical frameworks e.g., health 
behaviors, negative emotional reactions related to a positive HPV test result. Negative attitudes 
toward delayed start of screening (i.e. 25 years) and/or increased screening interval to 5 or 10 
years and negative emotions and perceptions related to HPV testing are possible barriers to HPV 
test acceptability. In the context of the latest recommendations[12-17] for primary screening for 
cervical cancer and ongoing plans of health authorities[14, 51-57] to implement HPV testing in 
primary cervical screening, addressing these attitudes and concerns should become part of the 
strategy to ensure a successful implementation of HPV test-based screening programs.  
We found that women’s increased HPV and HPV test knowledge and using information 
channels represent a possible facilitator of HPV test acceptability. Since women in the USA, 
Australia and UK were found to have low HPV[58] and HPV test knowledge[59], strategies that 
increase women’s knowledge might also increase HPV test acceptability.  
Healthcare providers play an important role in promoting preventive health measures; as 
our team has previously demonstrated, discussing with HCP’s about HPV vaccination 
significantly increased acceptability of the HPV vaccine for their sons[60]. However, when 
HCPs are unknowledgeable about, or uncomfortable with, recommendations, it can negatively 
impact preventive health behaviors. In the context of cervical cancer screening, Boone et al. 
(2016) found that US HCP’s (e.g., , OB/GYN, family physicians), contrary to existing guidelines 
for women aged 30 to 65 years[17], recommended HPV co-testing on an every 3 year basis 
instead of 5 years[61]. Similar results were obtained in Italy by Cagliotti et al. (2017), who found 
that in women older than 30 years, 83.8% of gynecologists prefer to use the Pap test in primary 
screening, and only 44.9% of gynecologists knew that a negative HPV-DNA test allowed an 
increase in the screening interval to 5 years [62]. Moreover, 20% of participants believed that 
HCP are insufficiently prepared to explain either positive or negative HPV test results to their 
patients[62]. In our opinion, especially in health systems where cervical cancer screening is 
opportunistic, an age-appropriate HCP recommendation for HPV testing could increase women’s 
HPV test acceptability as primary cervical cancer screening. Efforts are therefore needed to 
increase HCPs’ awareness of, and comfort with the latest guidelines.  
Moreover, adequate HPV vaccination coverage of females is important for secondary 
prevention of cervical cancer, as we found that women who were not vaccinated against HPV 
also had lower HPV test acceptability. Our results are concordant with results of a large US 
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study which showed that cervical screening initiation and interval adherence were significantly 
higher in women who had been vaccinated against HPV [63]. 
Since our review shows that attitudes and beliefs are important factors of HPV test 
acceptability but have been measured with scales that were not rigorously psychometrically 
tested[40, 44, 50], we recommend that future research address this knowledge gap. While a 
comprehensive and psychometrically validated scale for measuring HPV knowledge has been 
published[64], in our opinion, the only validated HPV test knowledge scale available[59, 65] 
needs to be modified to include items related to differences between Pap and HPV testing[31-33] 
(e.g., reasons for doing a HPV instead of Pap test,), risks[29, 30] (e.g., pain, infection) and 
practicalities of the HPV test[31] (e.g., what it involves,).  
Our study is not without limitations. Because most included studies were observational, 
interventions are needed for assessing the effect of factors on HPV test acceptability. Given that 
HPV testing as primary screening has only recently been recommended and only in some 
countries, there is a paucity of studies of psychosocial correlates of actual HPV testing uptake. 
Therefore, we defined HPV test acceptability comprehensively and included HPV test uptake as 
well as intentions/willingness to receive the HPV test in our synthesis. Our results relate to the 
overarching significant factors of organized or opportunistic screening environments, while some 
differences e.g., previous adherence to cervical screening are possible. We conducted a 
sensitivity analysis by removing studies with high risk of bias[40, 42, 45] from our synthesis 
(i.e., integration of quantitative evidence) and results remained largely unchanged. However, the 
facilitator effects of using health information channels[42], being of white ethnicity[42] and the 
barrier effect of expressing negative attitudes towards delayed start of screening and/or increased 
screening interval to 5 or 10 years[40] require further validation. We encourage researchers to 
further study the effect of factors on women’s HPV test acceptability for which we found 
contradictory evidence i.e., cervical screening test preference, negative perceived emotional 
reaction to HPV results, the type of intervention, existing personal medical history and women’s 
age. These contradictory findings may be attributed to the heterogeneity of factors (outcomes), 
population and interventions measured across included studies.  
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Conclusions 
By synthesizing findings of both qualitative and quantitative studies, our review provides 
a wide perspective related to factors of HPV testing in primary cervical cancer screening. Our 
results can inform designing interventions to increase primary HPV-based cervical cancer 
screening uptake in high income countries, but even more so in low and middle income countries 
where the incidence of cervical cancer is highest and where, as suggested by previous 
research[66], implementing a primary HPV testing program could be lifesaving.  
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Figure 1. Integrative Mixed Methods Research Synthesis Design 
Figure 2. PRISMA Flowchart 
Figure 3. Influence of factors on HPV test acceptability 
Note: cc = cervical screening; HPV = human papillomavirus 
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Table 1. Study characteristics and risk of bias within studies 
First 
author, 
countr
y, year 
Aim 
Data 
collectio
n 
method 
Cytology 
screenin
g 
environ
ment 
Interven
tion 
(Yes/No) 
N Setting 
Partici
pant 
age  
Data 
analysis 
method 
 
Risk 
of 
bias 
with
in 
stud
ies 
(%)
* 
Acera 
et 
al.[1], 
Spain, 
2014 
To 
determine 
the most 
effective 
intervention 
strategy to 
increase 
cervical 
cancer 
screening 
coverage in 
Barcelona 
Personal 
Interview  
Opportun
istic 
Yes 4775 
Primary 
Health 
Care 
centers in 
Cerdanyol
a, 
Barcelona 
60-70 
Chi-
square 
Low 
(67
%) 
Agenor 
et 
al.[2], 
USA, 
2017 
To examine 
the 
associations 
between 
sexual 
behavior 
and sexual 
identity, and 
lifetime 
HPV testing 
Survey 
administe
red by 
interview
er 
Opportun
istic 
No 11,300 
National 
probabilit
y sample  
15-44 
Multiva
riate 
logistic 
regressi
on 
Low 
(67
%) 
Alfaro 
et 
al.[3], 
El 
Salvad
or, 
2015 
To identify 
the 
facilitators 
and barriers 
to adherence 
to cervical 
cancer 
screening 
using HPV 
DNA testing 
in El 
Salvador  
Interview 
Opportun
istic 
Yes 409 
Salvadori
an 
Ministry 
of Health 
led 
Cervical 
Cancer 
Preventio
n HPV 
screening 
program 
30-49 
Univari
ate 
logistic 
regressi
on, chi 
square, 
multivar
iate 
logistic 
regressi
on 
Low 
(69
%) 
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First 
author, 
countr
y, year 
Aim 
Data 
collectio
n 
method 
Cytology 
screenin
g 
environ
ment 
Interven
tion 
(Yes/No) 
N Setting 
Partici
pant 
age  
Data 
analysis 
method 
 
Risk 
of 
bias 
with
in 
stud
ies 
(%)
* 
Burger 
et 
al.[4], 
Norwa
y, 2014 
To examine 
whether the 
contents of a 
cervical 
cancer 
screening 
invitation 
letter 
influence 
Norwegian 
women’s 
intent to 
participate 
in screening 
Web-
based 
survey  
Organize
d 
Yes 3540 
Represent
ative 
sample of 
Norwegia
n women 
25-69 
Univari
ate and 
multivar
iate 
Logistic 
regressi
on 
Low 
(81
%) 
Dieng 
et 
al.[5], 
Austral
ia, 
2013 
To 
investigate 
Australian 
women`s 
cervical 
cancer 
screening 
preferences, 
information 
needs and 
decision-
making 
styles  
Semi-
structure
d 
telephone 
interview 
Organize
d 
No 1279 
National 
survey 
conducted 
by the 
Hunter 
Valley 
Research 
Foundatio
n  
18-70 
Multiva
riate 
logistic 
regressi
on, 
descripti
ve 
statistics 
Low 
(64
%) 
Filade 
et 
al.[6], 
Nigeria
, 2017 
To explore 
the attitudes 
of pregnant 
women to 
the 
incorporatio
n of HPV 
DNA-based 
testing in 
routine 
ANC in 
Nigeria  
Focus 
groups 
Opportun
istic 
No 82 
Hospitals 
and health 
facilities 
in central 
Nigeria  
Mean 
28.9 
(SD = 
4.7) 
Qualitat
ive 
content 
analysis  
Low 
(90
%) 
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First 
author, 
countr
y, year 
Aim 
Data 
collectio
n 
method 
Cytology 
screenin
g 
environ
ment 
Interven
tion 
(Yes/No) 
N Setting 
Partici
pant 
age  
Data 
analysis 
method 
 
Risk 
of 
bias 
with
in 
stud
ies 
(%)
* 
Gerend 
et 
al.[7], 
USA, 
2017 
To 
investigate 
women’s 
acceptance 
of new 
cervical 
cancer 
screening 
guidelines  
Electroni
c Survey  
Opportun
istic 
No 376 
Online 
panel 
maintaine
d by 
Qualtrics 
21-65 
Descript
ive 
statistics 
High 
(58
%) 
Huang 
et 
al.[8], 
USA, 
2008 
To assess 
women’s 
interest in 
obtaining 
HPV testing 
as well as 
their 
preferences 
for 
concomitant 
Pap testing 
Telephon
e and in-
person 
interview
s  
 
Opportun
istic 
No 
Opportun
istic 865 
Communi
ty and 
university
-based 
practices 
50-80 
Multiva
riate 
logistic 
regressi
on 
Low 
(64
%) 
Jayasin
ghe et 
al.[9], 
Austral
ia, 
2016 
To assess 
women’s 
attitudes 
towards 
guidelines 
for HPV 
testing in 
cervical 
cancer 
screening  
Electroni
c Survey 
Organize
d 
No 125 
Social 
media  
16-28 
Fisher’s 
exact 
test, 
odds 
ratios 
High 
(60
%) 
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First 
author, 
countr
y, year 
Aim 
Data 
collectio
n 
method 
Cytology 
screenin
g 
environ
ment 
Interven
tion 
(Yes/No) 
N Setting 
Partici
pant 
age  
Data 
analysis 
method 
 
Risk 
of 
bias 
with
in 
stud
ies 
(%)
* 
Kwan 
et 
al.[10], 
China, 
2010 
To evaluate 
the effects 
of 
educational 
intervention 
on Chinese 
women’s 
intentions to 
be HPV 
tested 
Question
naire 
Opportun
istic 
Yes 292 
Family 
Planning 
Associati
on of 
Hong 
Kong’s 
(FPAHK) 
Wanchai 
Birth 
Control 
Clinic 
Mean = 
38.3 
(SD = 
7.41) 
Chi 
Square 
Low 
(88
%) 
Leon-
Maldon
ado et 
al.[11], 
Mexico
, 2016 
To assess 
the beliefs 
and 
perceptions 
of HPV and 
HPV testing 
among 
Mexican 
women who 
had 
participated 
in an early 
cervical 
cancer 
detection 
program  
Semi-
structure
d 
interview
s  
Opportun
istic 
No 24 
Two 
primary 
care 
health 
clinics in 
Michoacá
n state, 
Mexico 
30-65 
Themati
c 
framew
ork 
analysis 
Low 
(71
%) 
Marlow 
et 
al.[12], 
UK, 
2008 
To examine 
sociodemogr
aphic 
predictors of 
self-reported 
screening 
attendance, 
and 
intention to 
accept HPV 
testing. 
Home-
based, 
computer 
assisted 
interview
s 
Organize
d 
No 994 
National 
Centre for 
Social 
Research 
Omnibus 
Survey  
25-64 
Univari
ate and 
multivar
iate  
logistic 
regressi
on 
High 
(52
%) 
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First 
author, 
countr
y, year 
Aim 
Data 
collectio
n 
method 
Cytology 
screenin
g 
environ
ment 
Interven
tion 
(Yes/No) 
N Setting 
Partici
pant 
age  
Data 
analysis 
method 
 
Risk 
of 
bias 
with
in 
stud
ies 
(%)
* 
Marlow 
et 
al.[13], 
UK, 
2009 
To identify 
British 
women’s 
HPV and 
HPV test 
knowledge 
requirement
s  
Interview
s 
Organize
d 
No 21 
Universit
y College 
London 
18-53 
Themati
c 
framew
ork 
analysis  
Low 
(67
%) 
Nene et 
al.[14], 
India, 
2007 
To evaluate 
the 
sociodemogr
aphic 
variations in 
the uptake 
of cervical 
cancer 
screening in 
rural India   
Househol
d survey 
and 
hospital 
records 
Opportun
istic 
Yes 79,449 
Primary 
health 
centres, 
rural 
hospitals, 
and 
schools in 
the 
Osmanab
ad district 
in 
Maharash
tra state 
30-59 
Univari
ate and 
multivar
iate 
logistic 
regressi
on 
Low 
(71
%) 
Ogilvie 
et 
al.[15], 
Canada
, 2013 
To explore 
the impact 
of HPV 
testing on 
women’s 
intentions to 
be screened 
for cervical 
cancer  
Electroni
c Survey  
Organize
d in 
British 
Columbi
a 
Yes 981 
Provincial 
cervical 
cancer 
screening 
program 
at the 
British 
Columbia 
Cancer 
Agency  
25-65 
Chi 
square, 
t-test, 
multivar
iate 
logistic 
regressi
on  
Low 
(83
%) 
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First 
author, 
countr
y, year 
Aim 
Data 
collectio
n 
method 
Cytology 
screenin
g 
environ
ment 
Interven
tion 
(Yes/No) 
N Setting 
Partici
pant 
age  
Data 
analysis 
method 
 
Risk 
of 
bias 
with
in 
stud
ies 
(%)
* 
Ogilvie 
et 
al.[16], 
Canada
, 2016 
To describe 
factors 
associated 
with 
women’s 
intentions to 
be screened 
according to 
new 
guidelines 
for primary 
HPV DNA 
testing   
Electroni
c Survey  
Organize
d in 
British 
Columbi
a 
Yes 981 
Provincial 
cervical 
cancer 
screening 
program 
at the 
British 
Columbia 
Cancer 
Agency    
25-65 
Multiva
riate 
logistic 
regressi
on, 
Kruskal 
Wallis, 
chi-
square 
thematic 
analysis   
Low 
(81
%) 
Papa et 
al.[17], 
USA, 
2009 
To assess 
the impact 
of 
educational 
intervention 
on women’s 
acceptance 
of adjunct 
HR-HPV 
testing  
Question
naire 
Opportun
istic 
Yes 50 
Obstetrics 
and 
gynecolog
y faculty 
practice at 
the 
Universit
y of 
Massachu
setts 
Medical 
School/U
Mass 
Memorial 
Health 
Care 
30-69 
Fisher 
exact 
test 
High 
(55
%) 
Roland 
et 
al.[18], 
USA, 
2016 
To assess 
the impact 
of 
educational 
intervention 
on 
knowledge 
and beliefs 
of cervical 
cancer 
screening  
Survey 
Opportun
istic 
Yes 644 
Federally 
Qualified 
Health 
Center 
clinics in 
Illinois  
30-60 
Ordinal 
and 
binary 
logistic 
regressi
on 
Low 
(67
%) 
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First 
author, 
countr
y, year 
Aim 
Data 
collectio
n 
method 
Cytology 
screenin
g 
environ
ment 
Interven
tion 
(Yes/No) 
N Setting 
Partici
pant 
age  
Data 
analysis 
method 
 
Risk 
of 
bias 
with
in 
stud
ies 
(%)
* 
Schmid 
et 
al.[19], 
USA & 
Austral
ia, 
2017 
To 
determine 
the 
perceptual 
word 
associations 
that women 
hold with 
regards to 
cervical 
cancer 
screening 
tools in the 
US and 
Australia  
Electroni
c Survey  
Opportun
istic 
No 776 
Survey 
Monkey’s 
US and 
Australian 
databases  
18-64 
Co-
occurre
nce 
network 
graphs 
Low 
(64
%) 
Silver 
et 
al.[20], 
USA, 
2015 
To explore 
and 
understand 
women’s 
attitudes 
towards new 
cervical 
cancer 
screening 
options  
Interview
er-
administe
red 
survey 
Opportun
istic 
Yes 551 
Johns 
Hopkins 
Hospital 
affiliated 
outpatient 
OB/GYN 
clinics in 
Baltimore
, MD  
36-62 
Poisson 
regressi
on with 
robust 
error 
variance 
Low 
(67
%) 
Vansly
ke et 
al.[21], 
USA, 
2008 
To explore 
the 
knowledge, 
attitudes and 
beliefs 
related to 
cervical 
cancer, HPV 
and HPV 
testing of 
low-income, 
Hispanic 
women 
Focus 
groups 
Opportun
istic 
No  54 
Communi
ty-based 
settings in 
Albuquer
que, New 
Mexico 
18-60 
Themati
c 
analysis  
Low 
(69
%) 
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First 
author, 
countr
y, year 
Aim 
Data 
collectio
n 
method 
Cytology 
screenin
g 
environ
ment 
Interven
tion 
(Yes/No) 
N Setting 
Partici
pant 
age  
Data 
analysis 
method 
 
Risk 
of 
bias 
with
in 
stud
ies 
(%)
* 
Waller 
et 
al.[22], 
UK, 
2005 
To examine 
the 
understandin
g and beliefs 
about HPV 
and cervical 
cancer 
among 
women who 
have already 
participated 
in HPV 
testing  
Structure
d 
Interview
s  
Organize
d 
No 74 
Clinical 
trials of 
HPV 
testing 
and a 
colposcop
y clinic 
that 
utilizes 
HPV 
testing 
20-64 
Themati
c 
framew
ork 
analysis  
Low 
(64
%) 
Note: * percentage points were calculated as recommended by the authors of the Quality 
Assessment Tool for Studies with Diverse Designs (QATSDD); 100% reflects no risk of bias. 
For overall scores ≤60% and > 60% we report high and low risk of bias respectively  
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Highlights: 
 
 We used mixed methods research synthesis methodology, a form of systematic review  
 We provide a comprehensive categorization of psychosocial factors in HPV testing  
 Data integration enabled assessment of factors’ impact on HPV test acceptability 
 Assessed impact of factors: barriers, facilitators, contradictory evidence; no impact  
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